SVS Albion Olim UK Equity Fund Accumulation
|Dechra Pharmaceuticals PLC||7.65 %|
|Beazley PLC||5.33 %|
|BP PLC||4.89 %|
|Unilever PLC||4.73 %|
|GlaxoSmithKline PLC||4.35 %|
|Royal Dutch Shell PLC B||4.13 %|
|Vodafone Group PLC||4.08 %|
|Prudential PLC||4.03 %|
|Spectris PLC||3.93 %|
|Halma PLC||3.72 %|
|United Kingdom||100.00 %|
|Financial Services||18.62 %|
|Consumer Cyclical||12.18 %|
|Basic materials||7.48 %|
|Consumer Defensive||6.71 %|
|Communication Services||6.22 %|
Patrick joined the OLIM team in 2018 as a director and investment manager from stockbroker Baden Hill where he was Managing Partner. A highly experienced fund manager with over 25 years in the industry, Patrick has also worked for Jupiter Asser Management, Henderson Global Investors and M&G. Patrick is re-joining the team after working for OLIM from 2005-2009 and will be responsible for managing both equity and balanced portfolios.
Data provided by Morningstar.
The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.
This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.
You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.